Orthocell Ltd (ASX:OCC) managing director Paul Anderson sits down with Jonathan Jackson in the Proactive studio to discuss the company’s $3.5 million capital raise and the addition of some heavy hitting investors to the share register. The company is now cashed up to pursue its global market strategy of advancing its Striate+ bone repair and Remplir nerve repair products in international markets. The company is focused on a strategic regulatory program and the completion of a pivotal nerve repair study for US regulatory approval in 2024. It has also has also solidified a long-term partnership with the University of Western Australia.
Orthocell chair John Van Der Wielen said: “The support of these strategic investors is an endorsement of Orthocell’s science, business strategy and progress in commercialising its leading bone and nerve repair products, and the exciting outlook for the company as it progresses approvals in new key jurisdictions like the US."
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
